BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 31213797)

  • 1. Comparative analysis of medical expenditure with nebulized budesonide versus systemic corticosteroids in hospitalized patients with acute exacerbations of chronic obstructive pulmonary disease in China.
    Zhang J; Yao W; You X; Liu T; Liu Y
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1195-1207. PubMed ID: 31213797
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical Outcomes Of Using Nebulized Budesonide As The Initial Treatment For Acute Exacerbations Of Chronic Obstructive Pulmonary Disease: A Post-Hoc Analysis.
    Zheng JP; Zhang J; Ma LJ; Chen P; Huang M; Ou XM; Zhao ZW; Jiang SJ; Cao J; Yao W
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2725-2731. PubMed ID: 31819404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of Nebulized Budesonide in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease.
    Zhang R; Zhu J; Liu Y; Li Y; Liu W; Zhang M; Chen B; Zhu S
    Int J Chron Obstruct Pulmon Dis; 2020; 15():409-415. PubMed ID: 32161453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Clinical Outcomes Between Nebulized and Systemic Corticosteroids in the Treatment of Acute Exacerbation of COPD in China (CONTAIN Study): A Post Hoc Analysis.
    Chen Y; Liu Y; Zhang J; Yao W; Yang J; Li F; Lu L; Zheng J; Han X; Xu JF
    Int J Chron Obstruct Pulmon Dis; 2020; 15():2343-2353. PubMed ID: 33061352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of glucocorticoids in patients with COPD exacerbations in China: a retrospective observational study.
    Zhang J; Zheng J; Huang K; Chen Y; Yang J; Yao W
    Ther Adv Respir Dis; 2018; 12():1753466618769514. PubMed ID: 29692212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacies of nebulized budesonide and systemic corticosteroids in the treatment of exacerbations of chronic obstructive pulmonary disease: A systematic review and meta-analysis.
    Gu YL; Pang J; Sun ZX; Hu J; Sun Y; Wu XW; Guo JJ; Yang GS
    J Clin Pharm Ther; 2020 Jun; 45(3):419-429. PubMed ID: 31954070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nebulized Corticosteroids in the Treatment of COPD Exacerbations: Systematic Review, Meta-Analysis, and Clinical Perspective.
    Pleasants RA; Wang T; Xu X; Beiko T; Bei H; Zhai S; Drummond MB
    Respir Care; 2018 Oct; 63(10):1302-1310. PubMed ID: 30237276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
    Perrone V; Sangiorgi D; Buda S; Degli Esposti L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2749-2755. PubMed ID: 27853362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study.
    Roggeri A; Micheletto C; Roggeri DP
    Int J Chron Obstruct Pulmon Dis; 2014; 9():569-76. PubMed ID: 24940053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease.
    Woods JA; Wheeler JS; Finch CK; Pinner NA
    Int J Chron Obstruct Pulmon Dis; 2014; 9():421-30. PubMed ID: 24833897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, controlled multicentric study of inhaled budesonide and intravenous methylprednisolone in the treatment on acute exacerbation of chronic obstructive pulmonary disease.
    Ding Z; Li X; Lu Y; Rong G; Yang R; Zhang R; Wang G; Wei X; Ye Y; Qian Z; Liu H; Zhu D; Zhou R; Zhu K; Ni R; Xia K; Luo N; Pei C
    Respir Med; 2016 Dec; 121():39-47. PubMed ID: 27888990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steroids in acute exacerbations of chronic obstructive pulmonary disease: are nebulized and systemic forms comparable?
    Gunen H; Mirici A; Meral M; Akgün M
    Curr Opin Pulm Med; 2009 Mar; 15(2):133-7. PubMed ID: 19532028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials.
    Sivapalan P; Rutishauser J; Ulrik CS; Leuppi JD; Pedersen L; Mueller B; Eklöf J; Biering-Sørensen T; Gottlieb V; Armbruster K; Janner J; Moberg M; Lapperre TS; Nielsen TL; Browatzki A; Mathioudakis A; Vestbo J; Schüetz P; Jensen JU
    Respir Res; 2021 May; 22(1):155. PubMed ID: 34020641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual versus triple therapy in patients hospitalized for COPD in France: a claims data study.
    Dalon F; Roche N; Belhassen M; Nolin M; Pegliasco H; Deslée G; Housset B; Devillier P; Van Ganse E
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1839-1854. PubMed ID: 31692478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic corticosteroid for COPD exacerbations, whether the higher dose is better? A meta-analysis of randomized controlled trials.
    Cheng T; Gong Y; Guo Y; Cheng Q; Zhou M; Shi G; Wan H
    Clin Respir J; 2013 Oct; 7(4):305-18. PubMed ID: 23072733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exacerbation recovery patterns in newly diagnosed or maintenance treatment-naïve patients with COPD: secondary analyses of TICARI 1 trial data.
    Mannino DM; Clerisme-Beaty EM; Franceschina J; Ting N; Leidy NK
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1515-1525. PubMed ID: 29785101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial.
    Ismaila AS; Birk R; Shah D; Zhang S; Brealey N; Risebrough NA; Tabberer M; Zhu CQ; Lipson DA
    Adv Ther; 2017 Sep; 34(9):2163-2172. PubMed ID: 28875459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of nebulized inhaled corticosteroids among older adult patients: an assessment of outcomes.
    Marcus P; Oppenheimer EA; Patel PA; Katz LM; Doyle JJ
    Ann Allergy Asthma Immunol; 2006 May; 96(5):736-43. PubMed ID: 16729789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
    Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F
    Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK.
    Edwards SC; Fairbrother SE; Scowcroft A; Chiu G; Ternouth A; Lipworth BJ
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2851-2858. PubMed ID: 27920512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.